An official member of the European CRO Federation
We've merged with Palleos Healthcare to form a wide-reaching European CRO.
Find out more
Experience the benefits of running your next study in Eastern Europe
Contact our regional officeGermany (HQ)
Latvia
Poland
Romania
Hungary
Czech Republic
Spain
Ukraine
Bulgaria
Turkey
Brazil
the Netherlands
Georgia
Estonia
Lithuania
Belarus
Serbia
Russia
Kazakhstan
Croatia
Bulgaria
Moldova
Switzerland
We provide a full range of high-quality clinical trial services for Phase I-IV and BE studies. We offer both full-service clinical study engagements and standalone services.
We have worked with OCT on two separate occasions and have always been impressed by their professionalism and expertise.
James Barder
CEO, Futura Medical
The study has been going on during challenging times, and I am proud of our joint recruitment efforts with OCT Clinical. Without their resilience, energy, amazing control, efficiency and cooperative approach we wouldn’t have got here so soon.
Andreas Gerward
CEO, Stayble Therapeutics
We are happy that we came across OCT Clinical to run the next phase of our clinical study. We have been impressed with the CRO’s portfolio and are counting on their professionalism and performance.
Yong Liu
CEO, Recbio
When clinical trials hit roadblocks, we are ready to step in. Each time we takeover an active trial, our experts create a study rescue plan focused on resolving current bottlenecks and study challenges and an expedited study schedule to get it back on track.
Request a Proposal
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
